The finalists of Biopharmaceuticals have been selected. At the Invest Pitch Perfect Boutique Healthcare Investor conference, six biopharmaceutical companies will introduce their approach to infectious diseases, the theme of this year’s track. Investment is scheduled to take place at Willis Building in Chicago from May 20-21. Investors serving as the biopharmaceutical track judge include: V Capital partner Ryan Kole; Matt Martin, Pathway Bioventures partner; Michael Schultz, Senior Director of Venture Capital Business at Portal Innovation.
To view the full agenda and register click here.
Here is a preview of the Biopharma track and field finalists shown in Invest Pitch Perfect.
Canurta Therapeutics antimicrobial resistance is a global threat and a critical public health issue. Canurta has developed a library of cannabis-derived molecules with anti-inflammatory and antimicrobial properties. Its study of virtual drug target interactions highlights the potential of Streptococcus cerebella, a compound derived from cannabis, to inhibit enzymes associated with biofilms. It shows that small algae can be redefined as antibacterial and antifungal agents resistant to microbial infections. The company has optimized cerebellar derivatives to enhance pharmacological characteristics, focusing its R&D on identifying lead candidates through molecular docking and simulation, efficiency tests of drug-resistant microorganisms, and evaluating synergies with other antimicrobials to eliminate resistance with non-aza-type antimicrobial agents, for example, as with non-aza-based candidates.
Promedixinc focuses on detecting sepsis early through non-invasive optical circulatory dysfunction monitoring. Sepsis is the leading cause of death in children and adults around the world. Rapid detection is the key to survival. Early signs of sepsis include impaired peripheral circulation. One easy way to identify the risk of sepsis is capillary supplementation time (CRT). Promedix “Perifrl” measures rapid, accurate and non-invasive diagnosis of CRT, as well as therapeutic interventions once the patient’s bedside has been performed, and ongoing monitoring. After nearly 600 patient observation studies at the Oregon University of Health and Science Medical Center, Perry Furl found that it was as accurate as blood lactate when predicting sepsis.
SIVEC Biotechnologies, Inc plans to become a global leader in providing breakthrough, design biotherapeutics. SIVEC uses its next-generation intracellular biological drug delivery platform to develop a first-class pipeline focused on cancer, genetic and respiratory diseases. BACTPAC is a solution for all-in-one therapeutic payload production and target delivery. It is carefully designed to produce and safely deliver large and structured therapeutic payloads (mRNA, siRNA, protein/nanotype and CRISPR/CAS) to targeted tissues and tumors. It evades immune recognition and neutralizes antibodies, allowing repeated administration of tissues and tumors that are inaccessible to other drug delivery systems.
Taxi pharmaceutical company is a clinical-stage company that has developed drug candidates that can reuse the most widely prescribed generics for antibiotic-resistant bacterial infections. Its state-of-the-art drug candidate, TXA709, is currently participating as a participant in the Phase I clinical trial of oral anti-MRSA treatment.
Clearsight Therapeutics, Inc focuses on the treatment of acute infectious conjunctivitis. ClearSight is developing the first over-the-counter eye drops to treat all forms of acute infectious conjunctivitis, commonly known as “pink eye.” Every year, pink eyes affect up to 6 million children and adults in the United States, and parents miss jobs as children are out of school, causing nearly $2 billion in wage losses. Current treatments include prescription antibiotics, which are effective only in 20% of bacterial cases; up to 80% of infections are viruses.
Yaso Therapeutics is a clinical-stage pharmaceutical company that develops anti-infective drug products as well as birth control pills. Its mission is based on a wide range of performance gatherings, developing cutting-edge therapeutic and prevention products, and focusing on women's health at a core effort.
photo: Wayne Studios in Osaka, Getty Images
